StockData
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. (DCOY) stock

DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.88−0.07 (-7.31%)

Close on Nov 18, 2026Market cap $576.56KP/E –Yield –

Decoy Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Decoy Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$14.84M. For fiscal 2025 it was -$12.61M. The highest annual figure on record is -$1.68M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.61M–
FY2024Dec 31, 2024-$5.73M–
FY2023Dec 31, 2023-$12.89M–
FY2022Dec 31, 2022-$31.84M–
FY2021Dec 31, 2021-$12.81M–
FY2020Dec 31, 2020-$7.79M–
FY2019Dec 31, 2019-$8.27M–
FY2018Dec 31, 2018-$1.68M–
FY2017Dec 31, 2017-$34.73M–
FY2016Dec 31, 2016-$39.89M–
FY2015Dec 31, 2015-$29.21M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.63M–
Q1 FY2026Mar 31, 2026-$2.28M–
Q4 FY2025Dec 31, 2025-$9.03M–
Q3 FY2025Sep 30, 2025-$895.13K–
Q2 FY2025Jun 30, 2025-$965.57K–
Q1 FY2025Mar 31, 2025-$1.72M–
Q4 FY2024Dec 31, 2024-$1.49M–
Q3 FY2024Sep 30, 2024-$1.01M–
Q2 FY2024Jun 30, 2024-$1.47M–
Q1 FY2024Mar 31, 2024-$1.77M–
Q4 FY2023Dec 31, 2023-$970.70K–
Q3 FY2023Sep 30, 2023-$2.53M–
Q2 FY2023Jun 30, 2023-$3.97M–
Q1 FY2023Mar 31, 2023-$5.42M–
Q4 FY2022Dec 31, 2022-$6.48M–
Q3 FY2022Sep 30, 2022-$14.49M–
Q2 FY2022Jun 30, 2022-$4.76M–
Q1 FY2022Mar 31, 2022-$6.12M–
Q4 FY2021Dec 31, 2021-$4.14M–
Q3 FY2021Sep 30, 2021-$3.75M–
Q2 FY2021Jun 30, 2021-$3.12M–
Q1 FY2021Mar 31, 2021-$1.80M–
Q4 FY2020Dec 31, 2020-$1.76M–
Q3 FY2020Sep 30, 2020-$1.76M–
Q2 FY2020Jun 30, 2020-$1.90M–
Q1 FY2020Mar 31, 2020-$2.37M–
Q4 FY2019Dec 31, 2019-$2.06M–
Q3 FY2019Sep 30, 2019-$3.76M–
Q2 FY2019Jun 30, 2019-$912.10K–
Q1 FY2019Mar 31, 2019-$1.53M–
Q4 FY2018Dec 31, 2018-$2.02M–
Q3 FY2018Sep 30, 2018-$313.51K–
Q2 FY2018Jun 30, 2018-$9.10M–
Q1 FY2018Mar 31, 2018-$8.28M–
Q4 FY2017Dec 31, 2017-$8.09M–
Q3 FY2017Sep 30, 2017-$9.41M–
Q2 FY2017Jun 30, 2017-$8.88M–
Q1 FY2017Mar 31, 2017-$8.35M–
Q4 FY2016Dec 31, 2016-$7.98M–
Q3 FY2016Sep 30, 2016-$10.74M–

More Decoy Therapeutics figures

See a number that looks wrong?